<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    No articles found.

    Iovance Biotherapeutics, Inc.

    Iovance Biotherapeutics, Inc.

    Iovance Biotherapeutics (formerly traded as Lion Biotechnologies) is focused on th...

    Iovance Biotherapeutics (formerly traded as Lio...

    Precipio, Inc.

    Precipio, Inc.

    Precipio has built a platform designed to eradicate the problem of misdiagnosis by...

    Precipio has built a platform designed to eradi...

    T2 Biosystems, Inc.

    T2 Biosystems, Inc.

    T2 Biosystems, a leader in the development and commercialization of innovative med...

    T2 Biosystems, a leader in the development and ...

    Arcturus Therapeutics Holdings Inc.

    Arcturus Therapeutics Holdings Inc.

    Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of...

    Arcturus Therapeutics is developing portfolio o...

    Reata Pharmaceuticals, Inc.

    Reata Pharmaceuticals, Inc.

    Reata is a clinical-stage biopharmaceutical company that develops novel therapeuti...

    Reata is a clinical-stage biopharmaceutical com...

    Corbus Pharmaceuticals Holdings, Inc.

    Corbus Pharmaceuticals Holdings, Inc.

    Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical c...

    Corbus Pharmaceuticals Holdings, Inc. is a Phas...

    Alexion Pharmaceuticals, Inc.

    Alexion Pharmaceuticals, Inc.

    Alexion (NASDAQ: ALXN) is a global biopharmaceutical company focused on serving pa...

    Alexion (NASDAQ: ALXN) is a global biopharmaceu...

    BioCryst Pharmaceuticals, Inc.

    BioCryst Pharmaceuticals, Inc.

    BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...

    BioCryst Pharmaceuticals discovers novel, oral ...

    BioMarin Pharmaceutical Inc.

    BioMarin Pharmaceutical Inc.

    At BioMarin, we focus on developing first-in-class and best-in-class therapeutics ...

    At BioMarin, we focus on developing first-in-cl...